| Date | Title | Description |
| 06.04.2026 | Biotech Firm Gets a New Leader
New chief chosen | - |
| 02.04.2026 | CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala | SHANGHAI, April 2, 2026 /PRNewswire/ -- The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. Th... |
| 31.03.2026 | Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland | Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters
Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support
Plans further... |
| 31.03.2026 | Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare ex... | Alfasigma S.p.A (“Alfasigma” or the “Company”), a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered, today announced its financial results for the fiscal year 2025. Its results reflect a year of str... |
| 27.03.2026 | Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week | Novartis’ acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company’s existing allergy portfolio.
It comes just a week after Novartis announced it is acquiring Synnovation subsidiary Pikavation Thera... |
| 26.03.2026 | Hengrui Pharma Announces Strong 2025 Annual Results | SHANGHAI, March 26, 2026 /PRNewswire/ -- On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation and globalization. Revenue increased 13% y... |
| 24.03.2026 | Gilead покупает Ouro Medicines более чем за $2 млрд и усиливает ставку на иммунологию | По условиям сделки Gilead выплатит инвесторам Ouro $1,68 млрд авансом наличными, а также еще до $500 млн в случае достижения определенных этапов разработки препарата. Ключевым активом в этой покупке является экспериментальный препарат OM336... |
| 24.03.2026 | WuXi Biologics Reports Record 2025 Annual Results | Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY
IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps)
EBITDA rose 38.1%... |
| 24.03.2026 | DualityBio (9606.HK) Announces 2025 Annual Results | HONG KONG, March 24, 2026 /PRNewswire/ -- Duality Biotherapeutics, Inc. (Hong Kong Stock Exchange Code: 09606.HK, hereinafter referred to as "DualityBio" or the "Company"), a leading global clinical-stage innovative biop... |
| 23.03.2026 | Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss | Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial.
Pfizer said not enough people contracted Lyme disease to be confident in the results, but cited “strong efficacy” for its ... |
| 18.03.2026 | Breakout Ventures: $114 Million Fund III Launched To Back Frontier Science Startups | Breakout Ventures has announced the close of its $114 million Fund III, marking a new phase of investment focused on science-driven startups at the intersection of biology, chemistry, and artificial intelligence.
The San Francisco-based ven... |
| 12.03.2026 | ELRIG Announces Prof Hazel Screen and Dr Dave Powell as Keynote Speakers for Advances in Cell-based Screening 2026 | • Free-to-attend conference takes place at AstraZeneca in Gothenburg, Sweden from 6–7 May • Programme to focus on advancement of animal-replacement technologies and transition towards human-first, AI-driven drug discovery
Cambridge, UK, 12 ... |
| 10.03.2026 | Biocaptiva Secures £1.58M, Unveils Pioneering Liquid Biopsy Tech in US | Biocaptiva, an Edinburgh biotech firm, secured £1.58M in new funding. They launched their innovative msX magnetic bead technology in the US. This platform extracts cell-free DNA directly from whole blood. It eliminates traditional liquid bi... |
| 10.03.2026 | FDA approves leucovorin as first drug for rare genetic disorder, after touting it as autism treatment | The Food and Drug Administration approved a decades-old prescription vitamin called leucovorin as the first treatment for a rare genetic disorder in certain adults and children.
The move comes months after the Trump administration touted le... |
| 10.03.2026 | Breakout Ventures: $114 Million Fund III Launched To Back Science-Driven Startups Using AI | Breakout Ventures announced the close of its $114 million Fund III, expanding the venture firm’s efforts to back early-stage companies working at the intersection of science, technology, and artificial intelligence. The San Francisco-based ... |
| 10.03.2026 | Bright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: Report | - |
| 10.03.2026 | FDA finds little evidence that a drug touted by Trump can help people with autism | Getting your Trinity Audio player ready...
By MATTHEW PERRONE, AP Health Writer
WASHINGTON (AP) — The Food and Drug Administration on Tuesday approved a generic medication for a rare brain disorder, while walking back statements by Presiden... |
| 09.03.2026 | University of Edinburgh biotech spin-out BIOCAPTIVA raises £1.58M | University of Edinburgh spin-out BIOCAPTIVA has raised £1.58 million in a new funding round and launched its first product in the US.
BIOCAPTIVA’s novel magnetic bead technology is designed to solve one of liquid biopsy’s biggest bottleneck... |
| 03.03.2026 | Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform | NEW YORK, March 3, 2026 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty ... |
| 26.02.2026 | GSK calls for more conversations on shingles prevention in adults | - |
| 25.02.2026 | ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing | ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data from its phase 1 study of long-acting formulations of VH184, the first, third-generation integrase str... |
| 25.02.2026 | Британская GSK покупает канадскую биотехкомпанию 35Pharma за $950 млн | Компания GSK сообщила в среду, что согласилась выплатить $950 млн наличными за канадскую биотехнологическую компанию 35Pharma, что стало второй крупной сделкой нового генерального директора Люка Мийелса, направленной на ускорение разработки... |
| 25.02.2026 | ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen | ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced positive 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study.1 In adults livin... |
| 24.02.2026 | China's Frontier Biotech Pops After Granting GSK Rights to Two siRNA Drugs in USD1 Billion Deal | (Yicai) Feb. 24 -- Shares of Frontier Biotechnologies surged after the Chinese drugmaker granted UK pharmaceutical giant GSK the exclusive global rights to two small nucleic acid therapies it is developing in a deal worth more than USD1 bil... |
| 23.02.2026 | Moderna mRNA Flu Vaccine Gains FDA Review Amid Regulatory Shift | FDA will review Moderna's mRNA flu vaccine. This reverses an initial refusal. Moderna proposed a new regulatory path. It seeks full approval for adults 50-64. Accelerated approval is requested for ages 65 and up. A post-market study will fo... |
| 19.02.2026 | In reversal, US agrees to review new Moderna flu shot | NEW YORK: Vaccine manufacturer Moderna said Wednesday (Feb 18) the US Food and Drug Administration walked back its previous position and agreed to review the company's new mRNA-based flu shot.
Last week the US firm said the federal vaccine ... |
| 19.02.2026 | Altesa BioSciences: $75 Million Series B Raised For Advancing Vapendavir For Chronic Lung Diseases | Altesa BioSciences, a clinical-stage pharmaceutical company focused on improving outcomes for people with chronic lung diseases, has closed an oversubscribed $75 million Series B financing round to advance development of vapendavir, a first... |
| 19.02.2026 | Global Counsel to be placed into administration | Global Counsel’s 130 staff have been informed that the lobbying company founded by Peter Mandelson will be placed into administration as soon as tomorrow.
City AM understands that despite a number of clients deciding to stay with the firm, ... |
| 14.02.2026 | Mars Appoints Manish Syag as Managing Director for its Pet Nutrition Business in India | Delhi, India
Today, Mars, Incorporated announced the appointment of Manish Syag as Managing Director of its Pet Nutrition division in India. Manish will lead the business, home to some of the country’s most trusted and pioneering pet food b... |
| 11.02.2026 | CNBC’s UK Exchange newsletter: Compass shifts its trading to dollars — and it might not be the last | A recent change to the rules governing how companies may be admitted to indices, like the FTSE 100, run by FTSE Russell means those whose shares change hands in dollars and euros may now enter these indices.
It has prompted a couple of Foot... |
| 11.02.2026 | Global Counsel loses more clients as Epstein scandal deepens | The crisis engulfing the lobbying firm founded by Peter Mandelson, Global Counsel, deepened on Tuesday, after three more of its blue-chip clients parted ways with the advisory over its links to co-founder Mandelson and the convicted sex tra... |
| 10.02.2026 | Lobbying chief urges firms not to work with unregistered agencies | The boss of the lobbying sector’s industry body has urged public affairs chiefs to stop working with agencies that have not signed up to its code of conduct, after several blue-chip companies were forced to sever ties with Peter Mandelson’s... |
| 10.02.2026 | Mandelson’s Global Counsel has been rocked by its links to Epstein. Will it survive? | Global Counsel – the lobbying shop co-founded by Peter Mandelson – was once a swashbuckling force in London’s world-leading public affairs sector. But after the extent of its links to Jeffrey Epstein were revealed by the US Department of Ju... |
| 06.02.2026 | Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia | SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines, recently announced that its Group B meningococcal (MenB) vaccine candidate, DX-104, has received ... |
| 06.02.2026 | Cramer calls this drug maker the ‘greatest growth stock.’ He also names a runner-up | - |
| 06.02.2026 | PDA Introduces the 2026 Board of Directors and Officers | PDA's diverse Board of Directors brings a diverse set of interests, expertise, and experiences.
BETHESDA, Md., Feb. 6, 2026 /PRNewswire-PRWeb/ -- PDA is excited to introduce the all-volunteer 2026 Board of Directors and Officers following f... |
| 05.02.2026 | ‘Look out for rich individuals’: The deep ties between Mandelson lobbying firm and Epstein | As one of London’s many eminent lobbying and advisory outfits, Peter Mandelson’s Global Counsel is well versed in what it takes to manage a reputation.
Set up by the former deputy Prime Minister and Labour spin doctor Benjamin Wegg-Prosser ... |
| 04.02.2026 | Market Volatility Rocks US Stocks Amid Major Corporate Shifts and Mega-Mergers | US markets plunged. Tech and software stocks saw steep declines. Artificial intelligence concerns fueled investor anxiety. UBS reported robust earnings, beating forecasts. Its shares rose. Conversely, Novo Nordisk projected slowing growth. ... |
| 04.02.2026 | Santander falls nearly 4% amid plan to buy U.S. bank Webster for $12.2 billion | LONDON — European stocks opened in flat-to-higher territory on Wednesday amid a slew of corporate earnings reports in the region.
The pan-European Stoxx 600 was trading just above the flatline shortly after the market open.
The U.K.’s FTSE ... |
| 02.02.2026 | ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging | SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- On January 11, as the global healthcare industry gathered in San Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a ... |
| 01.02.2026 | AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China’s tempting innovation | AstraZeneca has announced it’s investing $15 billions in China, and said it is partnering with a Chinese biotech to develop weight-loss drugs.
The developments come at a critical time for the pharma industry as companies are increasingly lo... |
| 31.01.2026 | Britain's China Strategy: Billions Invested, Relations Realigned | UK Prime Minister Keir Starmer concluded a pivotal visit to China. He pursued stronger economic ties. AstraZeneca announced a $15 billion investment in Chinese pharmaceuticals. A visa-free travel deal was secured for UK citizens visiting Ch... |
| 30.01.2026 | PharmNovo enhances its Board ahead of Phase II development | PharmNovo enhances its Board ahead of Phase II development
Fri, Jan 30, 2026 08:04 CET Report this content
PharmNovo AB announces changes to its Board of Directors, welcoming two new members as the company prepares for its next phase of cli... |
| 29.01.2026 | uMotif Posts Strong Growth, Earns Market Accolades for eCOA Platform, Demonstrates Continued Clinical Trial Industry Leadership in 2025 | Everest Group gives uMotif highest possible technology rating in eCOA market assessment; Chief Scientific Officer Florence Mowlem PhD leads C-Path publication of industry-wide Event-Driven eDiary best practices in Nature Digital Medicine; f... |
| 29.01.2026 | Британская AstraZeneca планирует инвестировать $15 млрд в Китай до 2030 года | Компания с штаб-квартирой в Кембридже (Англия) заявила, что инвестиции помогут «создавать лекарства нового поколения».
«Сегодняшняя знаковая инвестиция в $15 млрд открывает захватывающую новую главу для AstraZeneca в Китае, который стал клю... |
| 29.01.2026 | Starmer: Businesses ‘cry out’ for more trade with China | Keir Starmer has said businesses are “crying out for ways” to export to Chinese markets as he struck a new deal for British travellers.
After meeting President Xi Jinping in China, Starmer defended his government’s ambitions to boost relati... |
| 29.01.2026 | New Board of Directors at Everdrone ahead of accelerated expansion | New Board of Directors at Everdrone ahead of accelerated expansion
Thu, Jan 29, 2026 09:53 CET Report this content
Everdrone AB announces the appointment of a new Board of Directors, following a decision at an Extraordinary General Meeting ... |
| 29.01.2026 | ‘No comment’: City firms on Starmer China trip keep schtum | When Sir Keir Starmer boarded a British Airways flight to Beijing earlier this week, he brought with him a coterie of leaders from British industry to help fly the flag.
More than 50 delegates were invited on the PM’s trip, many from top Ci... |
| 28.01.2026 | Airbus, AstraZeneca and HSBC executives join UK’s Starmer on high-stakes China trip | Starmer brings nearly 60 business and cultural groups on first U.K. leader visit to China in eight years.
Talks with Xi and Li focus on trade, investment and national security.
Visit follows a surge of foreign leaders engaging Beijing amid ... |
| 28.01.2026 | CNBC Daily Open: Starmer’s high stakes visit to China takes center stage | British businesses to join Starmer’s China visit.
S&P 500 marks record close.
A partial U.S. government shutdown.
Amazon accidentally sends email confirming cloud unit layoffs.
Two ways to play the energy sector.
All eyes are on U.K. Pr... |
| 28.01.2026 | Sigrid Therapeutics appoints Claus Kjaersgaard as Chief Executive Officer | Sigrid Therapeutics appoints Claus Kjaersgaard as Chief Executive Officer
Wed, Jan 28, 2026 08:30 CET Report this content
Stockholm, 28 January 2026 — Sigrid Therapeutics (Sigrid), a science-driven consumer health company developing innovat... |
| 28.01.2026 | Lib Dems: Starmer has gone ‘cap in hand’ to China despite spy threats | Keir Starmer has been accused of going “cap in hand” to China, piling further criticism on the government’s trade ambitions with a country that has backed hacking operations against the UK.
Liberal Democrats deputy leader Daisy Cooper deman... |
| 27.01.2026 | Starmer under fire over China trip amid phone-hacking revelations | Keir Starmer is under fire over his a trade-focused trip to China this week as further reports of espionage emerged.
Chinese officials are believed to have hacked the phones of key government officials, according to The Telegraph.
Hackers t... |
| 26.01.2026 | Andy Haldane: Labour has ‘no nose for business’ | The Labour government lacks anyone with a “nose for business”, Andy Haldane, the former chief economist of the Bank of England, has said in his latest critique against ministers’ quest for growth.
Haldane, whose criticism of Budget leaks la... |
| 25.01.2026 | GSK Bolsters Immunology Pipeline with $2.2B RAPT Acquisition | GSK made a significant strategic acquisition. The pharmaceutical giant purchased US biotech RAPT Therapeutics for $2.2 billion. This deal secures global rights to ozureprubart. Ozureprubart is an experimental, long-acting drug. It targets I... |
| 25.01.2026 | London's King's Cross: A Global Powerhouse Emerges | London's King's Cross has transformed into a global innovation and retail powerhouse. Once a neglected area, it now thrives as a leading tech and life sciences hub, attracting major investment and creating high-value jobs. Retail sales show... |
| 23.01.2026 | NVIDIA и Eli Lilly вложат $1 млрд в ИИ-лабораторию лекарств | NVIDIA и фармацевтический гигант Eli Lilly объявили о создании совместной ИИ-лаборатории с инвестициями до $1 млрд на пять лет. Лаборатория расположится в Сан-Франциско и объединит биологов и химиков Lilly с инженерами NVIDIA для круглосуто... |
| 22.01.2026 | King’s Cross retail sales boom as reinvention continues | King’s Cross retail sales rose by double digits last year as the zone’s reinvention attracts significant retail and leisure investment.
Total sales across the King’s Cross estate climbed by 13.5 per cent year on year, with retail sales up b... |
| 22.01.2026 | GSK Awards $2 Million In COiMMUNITY Grants To Help Close Vaccination Gaps And Pledges $3 Million for 2026 | GSK announced it has awarded $2 million in grants to 16 state, regional, and national nonprofit organizations through its COiMMUNITY Initiative, as the biopharma company seeks to support local efforts to improve vaccine education, communica... |
| 21.01.2026 | Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035 | BENGALURU, India, Jan. 21, 2026 /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol ... |
| 21.01.2026 | GSK приобретает компанию RAPT Therapeutics за $2,2 млрд | Сделка, одна из первых крупных в 2026 году, предусматривает выплату $58,00 за акцию при закрытии сделки, что оценивает общий капитал компании примерно в $2,2 млрд. Это существенно выше стоимости акций RAPT на закрытии 16 января, которая сос... |
| 20.01.2026 | GSK to acquire US-based biopharma company RAPT Therapeutics via a $2.2 billion deal — Details here | - |
| 20.01.2026 | Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology | DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. Under the terms of the agreement, Te... |
| 20.01.2026 | GSK to acquire US biotech group for $2.2bn | FTSE 100 giant GSK has reached an agreement to acquire US based biotech group Rapt Therapeutics.
The deal values the company, which develops therapies for treating people with inflammatory and immunologic diseases, at $2.2bn (£1.6bn), and m... |
| 16.01.2026 | Legal questions swirl around FDA’s new expedited drug program, including who should sign off | Getting your Trinity Audio player ready...
By MATTHEW PERRONE, Associated Press Health Writer
WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored by President Donald Tr... |
| 15.01.2026 | JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth | Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects
209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients
Complex m... |
| 13.01.2026 | At-home STD tests offer new options for screening and treatment | Getting your Trinity Audio player ready...
By MATTHEW PERRONE, AP Health Writer
WASHINGTON (AP) — New options for testing and treating some of the most common sexually transmitted diseases are becoming available, a trend that experts hope w... |
| 12.01.2026 | Haisco Grants Global Rights of Innovative Drug HSK39004 to AirNexis in Deal Exceeding USD 1 Billion | HSK39004, a novel dual‑target therapy, aims to compete in the global COPD market, highlighting innovation and international capabilities
BEIJING, Jan. 12, 2026 /PRNewswire/ -- On January 9, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticke... |
| 08.01.2026 | Peter Mandelson handed back £1.3m from consulting firm he founded | A consulting firm founded by Peter Mandelson handed back £1.3m to the House of Lords peer prior to his departure from the business, the firm’s latest accounts reveal.
Global Counsel, a London-based public policy consultancy launched by Mand... |
| 07.01.2026 | CNBC’s UK Exchange newsletter: Is Britain back? Five things to watch for the U.K. in 2026 | While 2025 was forgettable for the U.K. economy, there were some signs of improvement as it drew to a close.
From chancellor challenges to jobless-rate jitters, here are five things to watch for the U.K. economy in 2026.
This report is from... |
| 07.01.2026 | Big Pharma race to snap up biotech assets as $170 billion patent cliff looms | Some of the best-selling drugs in the world are facing a loss of exclusivity in key jurisdictions in the upcoming years in what the sector calls “the patent cliff.”
The need for pharma to top up their pipelines coincides with the broader bi... |
| 06.01.2026 | Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report | Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient care
LONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative i... |
| 31.12.2025 | London Stock Exchange needs more ‘hustle’ to attract IPOs, says Octopus chief | The boss of Octopus Energy Group has said the London Stock Exchange needs to show more “hustle” to attract new listing candidates like the group’s tech arm, Kraken.
Greg Jackson, chief executive of Octopus, said whilst he would “love” for K... |
| 22.12.2025 | GSK strikes deal to cut drug prices with US government | GSK has struck a voluntary agreement with the US government to lower the cost of prescription medicines and expand access to treatments for millions of Americans.
The move comes as pressure mounts on global drugmakers over pricing, tariffs,... |
| 20.12.2025 | US Drug Prices Face Seismic Shift: Pharma Giants Negotiate Deep Cuts | The American healthcare landscape is transforming. US drug prices, long the world's highest, face unprecedented pressure. President Trump drove an aggressive campaign to lower prescription costs. His administration pushed the Most Favored N... |
| 20.12.2025 | Telecom Visionary Ellis Hill Retires. ResearchFirst Acquired. New Leadership Drives Future. | ResearchFirst, Inc. (RFI) founder Ellis Hill retires December 31, 2025, concluding a remarkable 53-year career. Hill, a telecommunications visionary, pioneered Caller ID and advanced global SS7 services. His work transformed communication w... |
| 19.12.2025 | Ellis D. Hill, Founder and CEO of ResearchFirst, Inc., Announces Retirement | Wayne Chambers will continue RFI's legacy of innovation and service as Hill concludes a distinguished 53-year career.
GULFPORT, Miss., Dec. 19, 2025 /PRNewswire-PRWeb/ -- Ellis D. Hill, Founder and Chief Executive Officer of ResearchFirst, ... |
| 19.12.2025 | Takeda Rises After AI-Developed Psoriasis Pill Trial Success | - |
| 19.12.2025 | Trump announces lower drug price deals with 9 pharmaceutical companies | Getting your Trinity Audio player ready...
By SALLY HO
U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Related Articles
Michael Jackson, Diana Ross and ... |
| 19.12.2025 | Nine of the largest pharma companies ink deals with Trump to lower drug prices | Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation’s drug prices to cheaper ones abroad.
Pfizer, ... |
| 19.12.2025 | This is how exposed European Big Pharma is to the U.S. | The U.S. is the biggest single market for most pharma and biotech firms.
Among the 10 largest biopharmaceutical companies in the Stoxx 600 health index, five get a majority of their total sales from the U.S.
AstraZeneca gets 42% of sales fr... |
| 18.12.2025 | Avantor Appoints Simon Dingemans to its Board of Directors | , a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Simon Dingemans to its Board of Directors, effective January 2, 2... |
| 16.12.2025 | Why MBX Capital is Betting $100M on the Link Between Industrial Toxins and Chronic Disease | What You Should Know:
– MBX Capital has secured over $100M in capital commitments to invest in early-stage biotech and health tech companies, specifically focusing on “deep health” solutions that address diseases linked to environmental tox... |
| 15.12.2025 | uMotif Chief Scientific Officer Leads Publication of Fundamental Work Detailing Industry-Wide Recommendations for Adopting Event-Driven eDiaries in Clinical Trials | On behalf of the Critical Path Institute (C-Path) Florence Mowlem PhD, led this much-needed project, providing 10 best practices for EDeD design and implementation to support clinical trial data capture, along with co-authors from Top 10 ph... |
| 15.12.2025 | European markets close higher but defense, pharma stocks falter | LONDON — European stocks ended the session in positive territory at the start of a busy week for Europe's central banks.
The pan-European Stoxx 600 provisionally ended the session up 0.8%, with most sectors and major bourses in the green.
I... |
| 12.12.2025 | Болезням прописали инструкцию | - |
| 01.12.2025 | UK and US agree to zero tariff deal on pharmaceuticals | The government has agreed to a major deal with Washington that will see the UK become the only country to secure zero import tariffs on pharmaceutical products into the US for at least three years.
The deal follows months of negotiations be... |
| 27.11.2025 | Obulytix Strengthens Senior Leadership with Key Executive and Board Appointments | Ghent, Belgium – November 27th, 2025 – Obulytix, the biotechnology company pioneering Precision Lysin Therapeutics (PLTs) — a novel class of targeted biologics designed as next-generation antibiotics — today announces the appointment of Guy... |
| 20.11.2025 | PolyModels Hub Secures €7.8M Series A with Backing from Greece’s Marathon Venture Capital | Greece, UK ~
Company:
PolyModels Hub, with a Greek co-founder, has announced a €7.8 million ($9 million) Series A funding round led by Molten Ventures, with participation from Marathon Venture Capital.
👯 Founders: Antonio Benedetti, Charala... |
| 13.11.2025 | John Apathy Joins DataJoint as Strategic Advisor, Strengthening Data and AI Leadership in Life Sciences R&D | , a leading informatics platform revolutionizing data management and analysis in scientific research and the life sciences sector, announced the appointment of John Apathy as a Strategic Advisor, deepening the company’s expertise in data-dr... |
| 07.11.2025 | Why shingles hits harder with diabetes | Listen
5 min
New: You can now listen to articles.
This audio is generated by an AI tool.
Chickenpox may seem like a childhood illness of the past, but the varicella-zoster virus that causes it never fully disappears. Decades later, it can r... |
| 30.10.2025 | Exclusive: Liz Kendall bets £55bn to close UK innovation gap | Britain’s new tech secretary, Liz Kendall, insists the government’s record £55bn R&D package marks a turning point for UK innovation, but with the country still lagging global rivals in key sectors, questions remain over whether even th... |
| 29.10.2025 | Saudi Arabia's Global Health Exhibition 2025 Puts Medtech and AI Innovation in the Spotlight Leaders unveiled how data-driven innovation and space research are shaping healthcare in Saudi Arabia and b... | Being held from October 27-30 in Riyadh, the ongoing Global Health Exhibition (GHE 2025) has so far explored how the future for healthcare transformation is being driven through medical technology, AI innovation, investment and internationa... |
| 29.10.2025 | /C O R R E C T I O N -- GSK/ | In the news release, Five social service agencies join Singapore's shingles awareness movement, issued 29-Oct-2025 by GSK over PR Newswire, we are advised by the company that the one of the community partner's name, should read "Lions ... |
| 29.10.2025 | GSK shares jump as profit upgrade defies tariff gloom | Shares in GSK climbed as much as three per cent to 1,705p on Wednesday morning as the pharma giant defied tariff fears with an upgrade to its profit guidance.
The London-based business said it now expects turnover to increase by six to seve... |
| 27.10.2025 | FDA одобрило препарат GSK для лечения рака крови | - |
| 22.10.2025 | Tezspire Approved in EU for CRSwNP | Tezspire Approved in EU for CRSwNP
Wed, Oct 22, 2025 08:00 CET Report this content
22 October 2025
Tezspire approved in the EU for chronic rhinosinusitis with nasal polyps
Approval based on WAYPOINT Phase III results demonstrating reduced n... |
| 22.10.2025 | New survey shows nearly 70% of older adults in Singapore underestimate their risk of shingles; only 1 in 4 plans to consult their doctor on prevention | A survey by Ipsos, sponsored by GSK, found that while 63% of adults aged 50 years or over in Singapore were aware of shingles, only 29% recognised that 1 in 3 may develop the disease in their lifetime.
Less than half of respondents (44%) un... |
| 20.10.2025 | Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances | SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around ... |
| 14.10.2025 | Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults | -- Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection --
-- Increases in neutraliz... |
